Klinikum der Universität München-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2023

  1. Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma

    Nature Communications, Vol. 14, Núm. 1

2021

  1. Analysis of telomere maintenance related genes reveals NOP10 as a new metastatic-risk marker in pheochromocytoma/paraganglioma

    Cancers, Vol. 13, Núm. 19

2019

  1. Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/ mTOR axis in metastatic pheochromocytoma/ paraganglioma

    Theranostics, Vol. 9, Núm. 17, pp. 4946-4958

  2. Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-PronO study): A European network for the study of adrenal tumors retrospective study

    Journal of Clinical Endocrinology and Metabolism, Vol. 104, Núm. 6, pp. 2367-2374

2018

  1. Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients

    Genetics in Medicine, Vol. 20, Núm. 12, pp. 1652-1662

2017

  1. PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics

    Journal of Molecular Diagnostics, Vol. 19, Núm. 4, pp. 575-588

2015

  1. DNA methylation profiling in pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers

    Clinical Cancer Research, Vol. 21, Núm. 13, pp. 3020-3030

  2. SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: A multicenter interobserver variation analysis using virtual microscopy: A Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T)

    Modern Pathology, Vol. 28, Núm. 6, pp. 807-821